News Release(2025)

October 23, 2025

Linzagolix Approved for Marketing in Taiwan

October 7, 2025

Licensing Agreement for "Linzagolix" with Searchlight Pharma in Canada

September 25, 2025

Notice Regarding Sale of Investment Securities (Result)

July 30, 2025

Licensing Agreement with Viridian Therapeutics for "Veligrotug" and "VRDN-003" in Treatment of Thyroid Eye Disease

July 29, 2025

Notice Concerning Revisions to Financial Results Forecast and Recording of Extraordinary Income

July 24, 2025

Notice Regarding Completion of Disposal of Treasury Stocks as Restricted Stock for Members of the Board and Corporate Officers

July 1, 2025

New Launch of TAVALISSE® for Chronic Idiopathic Thrombocytopenic Purpura Treatment in South Korea

June 24, 2025

Notice Concerning Disposal of Treasury Shares as Restricted Stock for Members of the Board and Corporate Officers

May 8, 2025

Notice Concerning the Results of the Acquisition of Treasury Shares, Through Off-Auction Treasury Share Repurchase Trading System (ToSTNeT-3), the Completion of Acquisition of Treasury shares and the Cancellation of Treasury Shares

May 7, 2025

The New Five-Years Medium-Term Management Plan "Beyond 80"

May 7, 2025

Notice Concerning Dividends of Surplus (Increase in Dividend)

May 7, 2025

Notice on the Acquisition of Treasury Shares, the Acquisition of Treasury Shares Through Off-Auction Own Share Repurchase Trading System (ToSTNeT-3) and the Cancellation of Treasury Shares

May 7, 2025

Notice Concerning Revision of the Executive Compensation System

April 1, 2025

The Opening of a new Office for Open Innovation in the Boston Area

March 31, 2025

Kissei Initiates Phase III Clinical Trial for GnRH Antagonist "Linzagolix" Indicated for Endometriosis

March 14, 2025

Kissei Initiates Additional Phase III Clinical Trial for Rovatirelin (KPS-0373) for the Treatment of Spinocerebellar Degeneration

February 26, 2025

Submission of New Drug Application for GnRH Antagonist "Linzagolix" Indicated for Uterine Fibroids, in Japan

January 21, 2025

Marketing Authorization for the Oral Spleen Tyrosine Kinase Inhibitor TAVALISSE® in South Korea

January 14, 2025

Notification of co-promotion agreement termination of Minirin Melt and Desmopressin formulations

January 7, 2025

Sub-licensing Agreement for the Oral Spleen Tyrosine Kinase Inhibitor TAVALISSE® with Tai Tien Pharmaceuticals in Taiwan